## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- (Currently Amended) A method for inhibiting the growth or proliferation of glioma 1. cancer cells in a subject suffering from glioma wherein said glioma cancer cells express malignin, said method comprising administering to said subject an effective amount of a first dosage of a composition comprising malignin wherein said administration of said dosage stimulates the immune system of said subject to produce and release antimalignin antibody that binds and inhibits said glioma cancer cells and wherein said malignin is a polypeptide of approximately 10,000 Daltons isolated from glioma cancer cells and wherein said polypeptide has having an amino acid composition of about 9 aspartic acid residues, about 5 threonine residues, about 5 serine residues, about 13 glutamic acid residues, about 4 proline residues, about 6 glycine residues, about 7 alanine residues, about 6 valine residues, about ½ of a cysteine residue, about 2 methionine residues, about 4 isoleucine residues, about 8 leucine residues, about 3 tyrosine residues, about 3 phenylalanine residues, about 6 lysine residues, about 2 histidine residues, and about 5 arginine residues and wherein said malignin elutes at a discreet spot of approximately  $0.91 \pm 0.02$  with reference to a standard of cytochrome C on a thin layer chromatogram when chromatographed on a plate of superfine SEPHADEX G-200 with a mobile phase of 0.5 M NaCl in 0.02 M Na<sub>2</sub>HPO<sub>4</sub>KH<sub>2</sub>PO<sub>4</sub> phosphate buffer having a pH between 6.6 and 7.0 typical Sephadex G-50 resin column of 40 cm in length, 2.5 cm in diameter, and 196 mL in volume at a pressure of 40 mm of Hg and a flow rate of 35 mL per hour in a buffer of 0.05 molar phosphate solution at pH 7.2.
- 2. (Previously presented) The method of claim 1 wherein the composition is administered as an approximately 1 mg dosage form.
- 3. (Original) The method of claim 1 further comprising administering a second dose of the composition ten days after administration of the first dosage.

Docket No: 13793/46702 Application No: 09/854,568 Response to November 19, 2008 Final Office Action

4. (Original) The method of claim 3 further comprising administering a third dose of the composition ten days after administration of the second dosage.

## 5-13. (Canceled)

(Currently Amended). A method for inhibiting the growth or proliferation of breast 14. cancer cells in a subject suffering from breast cancer wherein said breast cancer cells express Recognin-M, said method comprising administering to said subject an effective amount of a first dosage of a composition comprising Recognin-M wherein said administration of said dosage stimulates the immune system of said subject to produce and release anti-Recognin-M antibody that binds and inhibits said breast cancer cells and wherein said Recognin-M is a polypeptide of approximately 10,000 Daltons isolated from MCF-7 cells and wherein said polypeptide has having an amino acid composition of about 5 threonine residues, about 5 serine residues, about ½ of a cysteine residue, about 1 methionine residue, about 6 valine residues, about 4 isoleucine residues, about 3 phenylalanine residues, about 6 lysine residues, about 2 histidine residues, about 5 arginine residues, about 9 aspartic acid residues, about 11 glutamic acid residues, about 8 leucine residues, about 2 tyrosine residues, about 4 proline residues, about 9 glycine residues, and about 9 alanine residues, and wherein said Recognin-M elutes at a discreet spot of approximately 0.9 with reference to a standard of cytochrome C on a thin layer chromatogram when chromatographed on a plate of superfine SEPHADEX G-200 with a mobile phase of 0.5. M NaCl in 0.02 M Na<sub>2</sub>HPO<sub>4</sub>KH<sub>2</sub>PO<sub>4</sub> phosphate buffer having a pH between 6.6 and 7.0 typical Sephadex G-50 resin column of 40 cm in length, 2.5 cm in diameter, and 196 mL in volume at a pressure of 40 mm of Hg and a flow rate of 35 mL per hour in a buffer of 0.05 molar phosphate solution at pH 7.